MP11-Rheumatology
Precision Medicine / IBS-MP11
GROUP OBJECTIVE: Delve into the pathogenesis of rheumatoid arthritis. Genetic-molecular bases of rheumatoid arthritis: identification of genetic markers of predisposition and prognosis. To highlight its participation in National and International Projects of competitive financing, Collaboration in different projects with the SER/FER and the SAR/FAR, Collaboration in competitive financing projects with the Institute of Parasitology and Biomedicine López-Neyra (CSIC), with Centro of Genomics and Oncological Research (GENyO) and with the University of Granada.
Research lines
- Biomarkers of prognosis and clinical course
- Gene expression in autoimmune diseases
- Response factors to biological therapies
- Prognostic factors of evolution and therapeutic response
- Cardiovascular morbidity
- Polymorphisms in rheumatoid arthritis
- Cardiovascular risk in autoimmune rheumatological diseases
Research networks
- RIER - Research on Inflammation and Rheumatic Diseases
ISMAEL FRANCISCO AOMAR MILLAN
IMMACULATE JIMENEZ MOLEÓN
PILAR MORALES GARRIDO
ENRIQUE RAYA ALVAREZ
JUAN SALVATIERRA OSSORIO
RICARDO SANCHEZ PARERA
Image in Osteology
JOURNAL OF OSTEOPOROSIS AND MINERAL METABOLISM, 2023;
Molecular typing of canine parvovirus type 2 by VP2 gene sequencing and restriction fragment length polymorphism in affected dogs from Egypt
FRONTIERS IN MICROBIOLOGY, 2023;
FI: 6,064; Q1
Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study
PLOSONE, 2023;
FI: 3,7; Q2
Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2023;
FI: 5; Q2
Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study
ADVANCES IN THERAPY, 2023;
FI: 3,8; Q3
Hospitalization and mortality from COVID-19 of patients with rheumatic inflammatory diseases in Andalusia
CLINICAL RHEUMATOLOGY, 2022;
Dose-Dependent Effect of Melatonin on BAT Thermogenesis in Zucker Diabetic Fatty Rat: Future Clinical Implications for Obesity
ANTIOXIDANTS, 2022;
FI: 7,675; D1
Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients
RHEUMATOLOGY, 2022;
FI: 7,046; Q1
Biologic therapy in refractory neurobehcet's disease: a multicentre study of 41 patients and literature review
RHEUMATOLOGY, 2022;
FI: 7,046; Q1
Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
CLINICAL MEDICINE, 2022;
FI: 3,2; Q2
A new molecular classification to drive precision treatment strategies in primary Sjogren's syndrome.
NATURE COMMUNICATIONS, 2021;
FI: 14,919; D1
Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases.
ARTHRITIS & RHEUMATOLOGY, 2021;
FI: 10,995; D1
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
INTERNAL AND EMERGENCY MEDICINE, 2021;
FI: 3,397; Q2
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply..
INTERNAL AND EMERGENCY MEDICINE, 2021;
FI: 3,397; Q2
Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021;
FI: 4,473; Q2
Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients
RHEUMATOLOGY, 2020;
FI: 5,606; Q1
Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER)
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020;
FI: 4,751; Q1
Bacteremia in Systemic Lupus Erythematosus in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes
JOURNAL OF RHEUMATOLOGY, 2020;
FI: 3,35; Q2
Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more accrual damage and higher mortality
LUPUS, 2020;
FI: 2,251; Q3
Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry)
LUPUS, 2020;
FI: 2,251; Q3
Identification of a 3 '-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study
ARTHRITIS & RHEUMATOLOGY, 2019;
FI: 9,002; D1
Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behcet's Disease: National Multicenter Study of 177 Cases
ARTHRITIS & RHEUMATOLOGY, 2019;
FI: 9,002; D1
Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019;
FI: 5,072; Q1
Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept
PLOSONE, 2019;
FI: 2,776; Q2
Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated With Cardiovascular Disease in Rheumatoid Arthritis
FRONTIERS IN IMMUNOLOGY, 2019;
FI: 4,716; Q2
Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis
ANNALS OF THE RHEUMATIC DISEASES, 2018;
FI: 12,35; D1
Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus
SCIENTIFIC REPORTS, 2018;
FI: 4,122; Q1
Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis
PLOSONE, 2018;
FI: 2,766; Q1
The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern.
RHEUMATOLOGY INTERNATIONAL, 2018;
FI: 1,952; Q4
The beliefs of rheumatoid arthritis patients in their subcutaneous biological drugs: strengths and areas of concern (vol 38, pg 1735, 2018)
RHEUMATOLOGY INTERNATIONAL, 2018;
FI: 1,952; Q4
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis
AMERICAN JOURNAL OF HUMAN GENETICS, 2017;
FI: 9,025; D1
Lipoprotein (a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project
JOURNAL OF CLINICAL LIPIDOLOGY, 2017;
FI: 5,812; D1
Increased expression of microRNA-155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017;
FI: 3,528; Q1
Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis.
SCIENTIFIC REPORTS, 2017;
FI: 4,259; Q1
Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus.
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017;
FI: 4,498; Q1
IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus
ANNALS OF THE RHEUMATIC DISEASES, 2016;
FI: 12,384; D1
Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis.
SCIENTIFIC REPORTS, 2016;
FI: 5,228; Q1
Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyzes in a large cohort from the Spanish Society of Rheumatology Lupus Registry
RHEUMATOLOGY, 2016;
FI: 4,524; Q1
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis
PHARMACOGENOMICS JOURNAL, 2016;
FI: 3,784; Q1
Tacrolimus-induced gynecomastia in a patient with polymyositis
CLINICAL MEDICINE, 2016;
FI: 1,267; Q2
Real-life effectiveness of upadacitinib for early and sustained pain relief in radiographic axial spondyloarthritis (UPSTAND)
Funder: ABBVIE SPAIN SLU
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 16/03/2023 - 30/06/2025
PI: ENRIQUE RAYA ALVAREZ
Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pegozafermin in patients with severe hypertriglyceridemia (HTGG). ENTRUST
Funder: 89BIO INC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 12/09/2023 - 30/12/2024
IP: ISMAEL FRANCISCO AOMAR MILLAN
“Prospective, randomized, multicenter study to compare the efficacy at 52 weeks (1 year) of biosimilar teriparatide and alendronate in the prevention of new morphometric vertebral fractures and/or aggravation of previous vertebral fractures in women with clinical vertebral fracture or recent hip fracture (imminent risk of fracture) and low bone mineral density. IMMINENT Study
Financier: GEDEON RICHTER IBÉRICA SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 14/06/2022 - 30/12/2023
PI: ENRIQUE RAYA ALVAREZ
A multinational, noninterventional study of tofacitinib in patients treated for psoriatic arthritis. TOPSATI. PFI-TOF-2020-01
Financier: PFIZER HOLDING FRANCE
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 03/08/2022 - 30/01/2024
PI: ENRIQUE RAYA ALVAREZ
Evaluation of guselkumab (Tremfya®) and treatment with different IL-17 inhibitors in patients with psoriatic arthritis in routine clinical practice; cohort, observational and prospective study.
Funder: JANSSEN-CILAG INTERNATIONAL NV
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 19/11/2021 - 30/10/2027
PI: ENRIQUE RAYA ALVAREZ
Biological PsA: Retrospective observational study on anti-IL17 treatment patterns in the management of psoriatic arthritis. LIL-IXE-2020-01 (LY2439821)
Financier: LILLY, SA
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 06/10/2020 - 30/01/2021
PI: ENRIQUE RAYA ALVAREZ
Observational study of the persistence of treatment in psoriasic arthritis PRO-SPIRIT study. (LIL-IXE-2019-01)
Funder: ELI LILLY AND COMPANY
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 20/10/2020 - 30/12/2025
PI: ENRIQUE RAYA ALVAREZ